Brief: IO Biotech Announces Clinical Improvement In Progression Free Survival Demonstrated In Pivotal Phase 3 Trial Of Cylembio Plus KEYTRUDA (Pembrolizumab) For The Treatment Of First-Line Advanced Melanoma, But Statistical Significance Narrowly Missed
11/08/2025 13:55
Aug 11 (Reuters) - IO Biotech Inc IOBT.O: IO BIOTECH ANNOUNCES CLINICAL IMPROVEMENT IN PROGRESSION FREE SURVIVAL DEMONSTRATED IN PIVOTAL PHASE 3 TRIAL OF CYLEMBIO® PLUS KEYTRUDA® (PEMBROLIZUMAB) FOR THE TREATMENT OF FIRST-LINE ADVANCED MELANOMA, BUT STATISTICAL SIGNIFICANCE NARROWLY MISSED IO BIOTECH INC - CYLEMBIO PLUS KEYTRUDA WELL TOLERATED WITH NO NEW SAFETY SIGNALS IO BIOTECH INC - PLANS FDA MEETING THIS FALL FOR REGULATORY SUBMISSION Source text: ID:nGNX96gpYp Further company coverage: IOBT.O ((Reuters.Briefs@thomsonreuters.com;))